

## Burkitt Lymphoma Presenting as Left Lateral Rectus Palsy

Daniel Tseytlin DO  
Lehigh Valley Health Network, Daniel.Tseytlin@lvhn.org

Usman Shah MD  
Usman.Shah@lvhn.org

Follow this and additional works at: <https://scholarlyworks.lvhn.org/medicine>



Part of the [Hepatology Commons](#), [Medical Sciences Commons](#), and the [Oncology Commons](#)

Let us know how access to this document benefits you

---

### Published In/Presented At

Tseytlin, D., & Shah, U. (April 29, 2014). *Burkitt Lymphoma presenting as left lateral rectus palsy*. Poster presented at: LVHN Research Day, Allentown PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact [LibraryServices@lvhn.org](mailto:LibraryServices@lvhn.org).



# Burkitt Lymphoma Presenting as Left Lateral Rectus Palsy

Daniel Tseytlin, DO and Usman Shah, MD  
Lehigh Valley Health Network, Allentown, Pennsylvania

## Case:

- A 43 year old male approximately 2 weeks prior to initial hospital presentation had some left eye pain while shoveling snow. The following day he woke up with left eye pain and double vision. He was seen by his primary doctor who prescribed him eye drops to reduce the pain, but still had double vision. On physical exam he was found to have impaired left eye abduction and ptosis consistent with palsy of cranial nerves VI and III, respectively. He did not have other neurologic pertinent findings such as slurred speech, weakness, numbness, facial weakness. He was evaluated in the emergency department. Initially, his CT scan did not show any acute stroke. His first MRI showed no evidence of acute infarct but showed abnormal soft tissue fullness in the cavernous sinus, especially on the left with concern for lymphoma or leukemia with metastatic disease or sarcoidosis. Basic laboratories including CBC and CMP were within normal limits apart from a mildly elevated AST of 42.
- CT scan of chest, abdomen, and pelvis to uncover the source of cavernous sinus masses. Results showed gastric antral wall thickening (Fig 1), extensive peritoneal carcinomatosis, reticulonodular opacities within the lungs, a pancreatic tail mass, small bilateral renal lesions and upper abdominal lymphadenopathy. The patient was initially treated with palliative brain radiation until diagnosed with lymphoma.



Figure 1. Gastric antral wall thickening on CT.



Figure 2. Peritoneal carcinomatosis on CT.

Presentation	Differential
Unilateral Painful Vision Disturbance	<ul style="list-style-type: none"> <li>• Corneal abrasion or infection</li> <li>• Acute angle-closure glaucoma</li> <li>• Iritis/uveitis</li> <li>• Optic neuritis</li> <li>• Endophthalmitis</li> <li>• Cavernous sinus thrombosis/mass</li> </ul>
Diplopia	<ul style="list-style-type: none"> <li>• Thyroid disease</li> <li>• Cranial Neuropathy (CN III, IV, VI)</li> <li>• Neuromuscular disease (Myasthenia gravis)</li> <li>• Botulism, Miller-Fisher Syndrome</li> <li>• Encephalitis, Basilar meningitis</li> <li>• Brainstem Stroke</li> </ul>

- EGD and biopsy of the gastric lesion (Fig 3) as well as bone marrow biopsy (Fig 4, 5) of the iliac spine. Ki-67 index was very high >90%, c-MYC rearrangement was present, and his disease was determined to be stage IVB. Immunohistochemical studies:

CD20: (+)      Ki-67: (+) in      BCL-2: (-/ dim focal+)  
 CD10: (+)      approx. 90%      BCL-1: (-)  
 BCL-6: (+)      of nuclei      TdT: (-)




Figure 3. Gastric biopsy showing "starry sky" pattern.




Figure 4. Bone marrow showing lymphocytic vacuolization.




Figure 5. Bone marrow showing extensive necrosis.


## Discussion:

- Malignant metastasis to the central nervous system affects as many as 25% of patients with cancer.<sup>1</sup>
- Burkitt lymphoma (BL) is an uncommon<sup>2</sup> aggressive B-cell Lymphoma composed of rapidly proliferating B cells; it is considered the most highly aggressive NHL, with doubling times of 24 to 48 hours in some cases.<sup>3</sup>
- BL is subdivided into Endemic, Sporadic, and immunodeficiency-associated.
- Diagnosis of BL requires IHC staining for CD20+, CD10+ and TdT- with delineation from DLBCL by negativity for BCL-2.
- Translocation between MYC on chromosome 8 and one of three immunoglobulin chain loci results in overexpression of the MYC protein causing deregulation of cellular growth.<sup>3</sup>
- Initial presentation of BL as cavernous sinus syndrome is uncommon.<sup>4</sup>
- Patient underwent treatment with HyperCVAD with intrathecal Methotrexate for CNS prophylaxis.
- The patient's prognosis was calculated using the International Prognostic Index (IPI) for aggressive lymphoma<sup>5</sup>. The IPI is a model for predicting outcome based on patient clinical characteristics prior to treatment. Patients are stratified according to risk with implications for treatment modalities. Those at high risk who are not effectively treated with current regimens may benefit from new clinical trial therapeutics. There are 5 adverse prognostic risk factors based on features of tumor growth potential, patient response to tumor, and ability to tolerate therapy: 1) age > 60 yo, 2) Ann Arbor Stage III/IV, 3) > 1 extranodal site, 4) Serum LDH > normal, 5) ECOG performance status >= 2. (Score range 0 - 5).
- The patient's IPI : 2 (Stage IVB and >1 extranodal site) indicated a 5 year overall survival of 51% and complete response rate of 67%.

Stage	Cotswold Modification of Arbor Classification
I	Involvement of a single LN region or lymphoid structure.
II	Involvement of two or more LN regions on the same side of the diaphragm (Mediastinum is considered a single site, but the hilar LNs are considered bilaterally); the number of atomic sites should be indicated by a subscript (e.g., II <sub>2</sub> ).
III	Involvement of LN regions on both sides of the diaphragm: III1 (with or without involvement of splenic hilar, celiac, or portal nodes) and III2 (with involvement of paraortic, iliac, and mesenteric nodes).
IV	Involvement of one or more extranodal sites in addition to a site for which the designation E has been used.

Risk Group	IPI Score	% Patients	5-year OS	Complete Response Rate
Low	0-1	35%	73%	87%
Low-Intermed	2	27%	51%	67%
High-Intermed	3	22%	43%	55%
High	4-5	16%	26%	44%

Figure 6. Prognosis Variables for NHL Subtypes<sup>5</sup>  
International Prognostic Index (1993)



## REFERENCES:

- Kased, N et al. Niederhuber: Abelloff's Clinical Oncology, 5th Ed: 725.
- Dunleavy, Kieron and Wilson, Wyndham H. Diagnosis and Treatment of Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma. Hoffman: Hematology: Basic Principles and Practice, 6th Ed: 1241-3.
- Wilson, Wyndham H. et al. Niederhuber: Abelloff's Clinical Oncology, 5th Ed: 2033, 2046.
- Vaphiades, MS et al. J Neuroophthalmol 2005; 25 (3):249-250.
- N Engl J Med. 1993;329:987-994.